湖南此次赴沪揽才，精准把握了当前人才市场的"供需关系"。从需求端看，众多岗位聚焦新一代信息技 术、先进制造、生物医药等领域——恰好与上海高校在集成电路、人工智能、生命科学等学科的优势高 度契合；从供给端看，湖南不只是给岗位，更注重"搭平台""优环境"："1+2"国家实验室体系、"4+4科 创工程"提供一流科研载体，职称评审破"四唯"，"最具幸福感城市"的生态又解决了生活后顾之忧。这 一套"产业有赛道、科研有支撑、生活有保障"的组合拳，向在沪学子展示了一张张充满机遇的"青春船 票"。 在复旦大学公共卫生专业就读的唐同学即将毕业，她表示这是第一次参加这么大型的招聘会，湖南带着 满满的诚意前来，让她感受到了人才被尊重，被爱护和被重视。"希望能够在这次招聘会上找到心仪的 岗位。" 现场，湖南省与复旦大学、上海交通大学、同济大学、华东师范大学签署合作协议，共同开启省校合作 新篇章。接下来，省校双方将立足"湖南所需"和"高校所能"，重点关注线上或点上可具象、可操作、可 落地的合作场景，以产业合作为主体，以科技、教育合作为补充，聚焦人工智能、量子计算、航空航 天、生物医药等领域开展深度合作，实现优势互补、良性互动，力争打造 ...

9 月 25 日， 2025 （第十九届） DEMO CHINA 在杭州圆满落幕。 本届大会由创业邦主办，由杭 州市拱墅区人民政府指导，拱墅区委人才办、杭州大运河数智未来城管委会联合主办。 作为早期创业者被看见和被发现的最佳平台 ， 本届大会共吸引 590 余家企业报名，经过层层筛选， 126 家早期科技公司成功入围。大会现场，机器人 *智能硬件、人工智能创新应用、智能制造、医疗 科技以及高通创投 - 红杉中国创业大赛、海外人才等六大专场，为我 们带来硬核技术与前瞻商业构 想的集中呈现。 从初选到现场评审， DEMO CHINA 始终秉持 " 科学严谨 " 和 " 前 瞻视野 " 的原则，综合考量团 队背景、商业模式、产品服务、市场吸引力、运营状况、创新力及现场表现力等维度进行严格筛选。 参与展示的企业，平均成立时间仅有 2.76 年，均处于 A 轮及 A 轮前期，其中更有 16% 为尚未被 主流风险投资发现的 " 水下公司 " 。值得关注的是，这些企业创始人中硕士及以上占比高达 89% ，博士及博士后占比 65% ，超半数团队拥有海外经历，高知背景与国际视野成为早期科创团队的核 心底色。 大会现场， 经过多 ...

Core Viewpoint - The meeting between Nanjing's municipal leaders and the Hong Kong Provincial Political Consultative Conference delegation emphasizes the importance of enhancing economic and cultural cooperation between Nanjing and Hong Kong, particularly in the context of the Guangdong-Hong Kong-Macao Greater Bay Area and the Yangtze River Delta integration strategy [1]. Group 1 - The Hong Kong Provincial Political Consultative Conference is recognized as a significant force for patriotism and Hong Kong, serving as a connection for political consultative members and facilitating cooperation between Nanjing and Hong Kong [1]. - Both parties aim to expand economic and trade cooperation between Nanjing and Hong Kong, focusing on high-level openness and cultural exchanges [1]. - Key areas of collaboration include technological innovation, financial services, biomedicine, and cultural tourism, with the goal of attracting more Hong Kong businesses, investments, and young talents to Nanjing [1].

南方都市报、南都大数据研究院"信心有数"栏目，用数据记录广东实现现代化的奋进之路，用数据描绘 万马奔腾共创美好的活力之路，用数据书写每一个你我昂扬向上的信心之路。 千里之行，系于你我；心中有数，广东可期。 四海粤商，接帖集结！2025世界粤商大会定于9月28日至30日举行。届时，超1387亿资本将强势汇聚， 36个超十亿级项目将进行现场签约。全球粤商精英天团即将齐聚广州，共赴这场商界"武林盛会"！南都 大数据研究院本期"信心有数"带你提前看：这场盛会的"雄厚家底"与粤商群体的强劲实力。 粤商大会"粤"联四海 历经7届越办越有料 "信心有数"栏目 广东民企不仅在"大"，更胜在"活"和"新"。9月15日公布的2025中国企业500强榜单中，广东有54家企业 上榜，其中半数以上为民营企业。华为、腾讯、比亚迪等企业不仅在国内市场表现优异，更在全球创新 竞赛中实现从"跟跑"到"并跑"乃至"领跑"的转变。华为上半年研发投入969.5亿元，占营收22.7%；比亚 迪研发投入309亿元，同比增长53%；腾讯累计专利授权超4.6万项…… 这些成绩的背后，离不开广东对的"政策护航"。中华人民共和国民营经济促进法》今年施行后，广东 ...

Core Insights - The 2026 Shanghai University Graduates Autumn Campus Recruitment Fair was held, featuring over 1,000 employers offering 35,000 job opportunities across key industries such as integrated circuits, biomedicine, and artificial intelligence [1] - Shanghai is expected to have 258,000 university graduates next year, including 91,000 postgraduates, 113,000 undergraduates, and 54,000 vocational students [1] - A mechanism linking demand, enrollment, training, employment, and monitoring has been established in Shanghai to conduct comprehensive and long-term research on graduate employment status [1] Group 1 - The recruitment fair aims to address structural employment issues and enhance students' skill sets through pre-employment training systems [1] - The "Shanghai University Graduate Tracking Survey Sub-center" was established to support employment services for graduates [1] - Employers awarded certificates to representatives of 2025 Shanghai university graduates at the event, highlighting the importance of practical training [1]

越南科技部部长阮孟雄表示，该法将越共中央政治局关于推进科技创新和国家数字化转型突破发展 的第57号决议具体化，是一份以知识与创造力建设强盛国家的"宣言"。科技部副部长黎春定认为，该法 充分彰显越南破解长期制约科技创新与数字化转型发展制度瓶颈坚定决心，为支持全面创新、推动科研 与市场深度融合提供了法律框架。在企业发挥核心作用背景下，该法落地后有望涌现更多具有竞争力 的"越南制造"科技产品，带动越南企业更深入融入全球价值链。 "创新"首次正式纳入法律，与"科学"和"技术"并列。如果说科技侧重于新知识和技术研发，那么创 新则涵盖了从构想、试验到商业化的全过程，并强调全社会广泛参与。企业首次在法律条款中拥有独立 章节。该法鼓励企业利用自身资源和国家支持，大规模投资研发。 （原标题：《越南科技创新法》将于10月1日起生效） 该法不仅弥补了以往制度不足，更确立了一种全新思路：充分激发全社会创新创造活力，以企业为 核心，支持科研成果商业化并构建数字化基础。凭借诸多创新性、突破性举措，新法有望成为越南在融 入国际社会新阶段加速发展、提升国家竞争力的重要推动力。 越通社9月26日报道，《越南科技与创新法》将于10月1日起生效， ...

Core Viewpoint - 博瑞医药 plans to repurchase shares through centralized bidding, with a total amount between 10 million and 20 million yuan, and a maximum repurchase price of 139.77 yuan per share, which is 140.73% higher than the current price of 58.06 yuan, reflecting a significant increase in stock price of 92.57% year-to-date [1] Group 1: Share Repurchase Details - The repurchase will be funded by the company's own funds and is set to occur within 12 months [1] - The current stock price of 博瑞医药 is 58.06 yuan, with a year-to-date increase of 92.57% [1] - The maximum repurchase price is significantly higher than the current market price, indicating a strong confidence in the company's value [1] Group 2: Financial Performance - As of June 30, 博瑞医药 reported a decrease in revenue to 537 million yuan, down 18.28% year-on-year, and a net profit of 17.17 million yuan, down 83.85% year-on-year [2] - The number of shareholders decreased by 10.11% to 9,568, while the average circulating shares per person increased by 11.32% to 44,185 shares [2] Group 3: Dividend and Shareholder Information - 博瑞医药 has distributed a total of 246 million yuan in dividends since its A-share listing, with 129 million yuan distributed in the last three years [3] - As of June 30, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited and a new entrant, Innovation Drug, which holds 2.81 million shares [3]

指数涨幅全球领先 2024年9月24日，国新办一场关于金融支持经济高质量发展的新闻发布会，触发A股迎来"史诗级反 弹"——上证指数6个交易日内一度大涨近千点。"9·24"行情一周年，政策与信心共同铸就了A股市场新 蜕变，行情走势也逐渐从"脉冲式反弹"到"结构性慢牛"。 Wind数据显示，截至9月23日，过去一年A股总市值从68万亿元攀升至104万亿元，增加36万亿元；上证 指数累计上涨39%，深证成指涨62.3%，而创业板、科创50、北证50指数涨幅均超100%，涨幅全球领 先，且科技股领跑。 其中，超1400只个股股价实现翻倍，个人投资者与长期资金双向涌入，A股新增投资者开户数超3000万 户。同时，有近800只基金收益一年翻倍，居民资金通过被动型产品入市，推动指数化投资趋势延续。 1400余只个股翻倍 过去一年来，A股主要指数自"9·24"行情以来均大幅上涨。截至9月23日，上证指数累计上涨39%，深证 成指涨62.3%，而创业板、科创50、北证50指数涨幅分别达103.5%、118.9%、158%；此外，恒生指数 上涨43.4%。 相较而言，纳斯达克综合指数同期上涨25.6%，德国DAX、日经225指数 ...

Group 1 - The third Guangdong-Hong Kong-Macao Greater Bay Area Development Business Conference was held in Guangzhou, focusing on cross-border finance, commercial law, artificial intelligence, and biomedicine [1][3] - The Greater Bay Area's modern industrial system is becoming increasingly robust, with emerging industries such as artificial intelligence, fintech, and biomedicine thriving alongside Hong Kong and Macao's developed financial and service sectors [3] - Guangdong has been recognized as the best province for business environment in China for four consecutive years, with over 20 million business entities, accounting for 10% of the national total, and more than 900,000 enterprises [3] Group 2 - The conference emphasized the need for Hong Kong's business community to collaborate with mainland enterprises to optimize the international industrial and supply chains in the Greater Bay Area [5] - The Greater Bay Area aims to become a global economic center by enhancing research capabilities, developing industries, and providing quality financial services [5] - The launch of the Greater Bay Area Exhibition Industry Alliance and the release of the "Greater Bay Area Supply Chain Promotion Report" and "Temporary Arbitration Guidelines for the Guangdong Free Trade Zone" provide new professional insights for business decision-making [7]

Core Viewpoint - TaiLong Pharmaceutical experienced a stock price decline of 2.12% on September 25, with a current price of 6.46 CNY per share and a market capitalization of 3.707 billion CNY [1] Company Overview - TaiLong Pharmaceutical, established on August 31, 1998, and listed on November 5, 1999, is located in Zhengzhou, Henan Province. The company operates in the pharmaceutical manufacturing sector, focusing on traditional Chinese medicine, chemical drug manufacturing, and pharmaceutical wholesale [2] - The revenue composition of TaiLong Pharmaceutical includes 70.59% from drug manufacturing, 14.71% from drug research services, and 14.42% from drug material circulation [2] - As of June 30, 2025, the number of shareholders is 40,900, a decrease of 11.14%, with an average of 14,037 circulating shares per person, an increase of 12.53% [2] Financial Performance - For the first half of 2025, TaiLong Pharmaceutical reported a revenue of 762 million CNY, a year-on-year decrease of 17.77%, and a net profit attributable to shareholders of 19.35 million CNY, down 27.32% year-on-year [2] - The company has distributed a total of 112 million CNY in dividends since its A-share listing, with 15.53 million CNY distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the seventh largest circulating shareholder is Guangfa Pension Index A, holding 3.236 million shares as a new shareholder, while Huatai-PineBridge CSI Traditional Chinese Medicine ETF has exited the top ten circulating shareholders [3]